drugset / Trial / NCT07160283
The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer
Phase 2
Not yet recruiting
96 enrolled
The Second Affiliated Hospital of Shandong First Medical University
NaSingle-groupOpen-labelTreatment
Summary
Evaluate the efficacy and safety of Trilaciclib for myeloprotection prior to chemotherapy in advanced cholangiocarcinoma or pancreatic cancer.
Timeline
- Start
- 2025-09-01
- Primary completion
- 2027-09-01
- Completion
- 2028-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Trilaciclib | Unknown | 240 mg/m2 | Intravenous |